Elevated Cardiovascular Risk and Mortality in Type 2 Diabetes Mellitus Patients With Cannabis, Opioid, and Cocaine Use Disorders.

Authors

Fiona Mei-Jung Lu, Yan Qi Lim, Yu-Ting Yu, Shih-Kai Kao

Published in

Diabetes, obesity & metabolism. Volume 28. Issue 9. Pages 7993-8003. Epub Jun 15, 2026.

Abstract

To evaluate the association between substance use disorders (SUDs), cardiovascular disease (CVD), and all-cause mortality in patients with type 2 diabetes mellitus (T2DM).
Using the TriNetX Research Network, we performed a retrospective cohort analysis of adults aged ≥ 18 years diagnosed with T2DM between January 2016 and December 2022. Patients diagnosed with cannabis-, opioid-, or cocaine-related disorders within 1 year prior to their T2DM diagnosis were identified. Propensity score matching (PSM) was utilized to balance demographics, comorbidities, and medication use between the SUD and non-SUD cohorts.
After PSM, each group included 69 419 individuals. Over a 3-year follow-up period, the SUD cohort exhibited significantly elevated risks of acute myocardial infarction (HR 1.994; 95% CI 1.766-2.253), atrial fibrillation (HR 1.455; 95% CI 1.300-1.630), heart failure (HR 1.837; 95% CI 1.693-1.994), stroke (HR 1.524; 95% CI 1.354-1.715), and all-cause mortality (HR 1.420; 95% CI 1.359-1.483). Subgroup analyses demonstrated consistent risk elevations across all substance types, with the highest relative mortality risk observed in patients with opioid-related disorders. All associations were statistically significant (p < 0.001).
Co-occurring SUDs are strongly associated with increased risk of cardiovascular morbidity and all-cause mortality in T2DM patients. However, these associations should be interpreted cautiously due to potential residual confounding despite propensity score matching. These findings underscore the urgent need for integrated risk assessment alongside tailored preventive and therapeutic strategies in this high-risk population.

PMID:
42297744
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.